Abstract:  Type 2 diabetes mellitus （ T2DM）  is a common cause of chronic kidney disease （ CKD）  and increases the risk  of  cardiovascular  diseases.  On  the  basis  of  renin⁃angiotensin⁃aldosterone  system  inhibitors  （ RAASi）  therapy， sodium⁃glucose cotransporter2 inhibitors  （ SGLT2i）  and  non⁃steroidal  mineralocorticoid  receptor  antagonists  （ MRA）  can both delay the progression of CKD and reduce the incidence of cardiovascular events. However， patients still face a higher risk of  adverse  cardiorenal  outcomes.  With  the  introduction  of  “ multifactorial  therapy，”  the  combination  of  RAASi， SGLT2i， and  non⁃steroidal  MRA  has  emerged  as  a  promising  therapeutic  option.  This  review  primarily  discusses  the mechanisms of  action  of  non⁃steroidal  MRA  and  SGLT2i  on  the  heart  and  kidneys，  as  well  as  the  impact  of  their combination on major clinical outcomes in T2DM patients.

Key words: nonsteroidal  mineralocorticoid , receptor , antagonist , odium?glucose , cotransporter?2 , inhibitors , type  2 diabetes mellitus, chronic kidney disease